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PURPOSE. Chronic central serous chorioretinopathy (cCSC) has recently been associated to
variants in the complement factor H gene. To further investigate the role of the complement
system in cCSC, the genomic copy number variations in the complement component 4 gene
(C4) were studied.
METHODS. C4A and C4B copy numbers were analyzed in 197 cCSC patients and 303 healthy
controls by using a Taqman copy number determination assay. Copy numbers of C4A, C4B,
and the total C4 load were compared between cases and controls, by using a Fisher exact test.
For this analysis Bonferroni correction was performed for three tests, and P values < 0.017
were considered to be significant. A logistic regression model was constructed to calculate
the odds ratios (ORs) of each of the C4B copy numbers, using two copies as a reference. For
this model P values < 0.05 were considered to be significant.
RESULTS. C4B genomic copy numbers differed significantly between cCSC patients and healthy
controls (P ¼ 0.0018). Absence of C4B significantly conferred risk of cCSC (P ¼ 0.039, OR ¼
2.61 [95% confidence interval (CI) ¼ 1.05–6.52]), whereas three copies of C4B significantly
decreased the risk of cCSC (P ¼ 0.014, OR ¼ 0.45 [95% CI ¼ 0.23–0.85]). The C4A genomic
copy numbers and total C4 load did not significantly differ between cases and controls.
CONCLUSIONS. This study showed that copy numbers of C4B are significantly associated with
cCSC. Carrying no copies of C4B significantly increases the risk of cCSC, whereas carrying
three C4B copies is protective. These findings reinforce the hypothesis of a possible
involvement of the complement system in the pathogenesis of cCSC.
Keywords: chronic central serous chorioretinopathy, cCSC, complement component 4, C4,
C4A, C4B
Chronic central serous chorioretinopathy (cCSC) is charac-terized by fluid accumulation under the neuroretina. It has
been postulated that this serous fluid derives from the choroid
and that it leaks through a dysfunctional retinal pigment
epithelium, causing a detachment of the neuroretina.1–4
Classically, cCSC patients are relatively young (middle-aged)
men who are still professionally active.5 Besides male sex, also
the use of corticosteroids, type A personality, and stress have
been associated with cCSC.4–6 Although the exact pathophys-
iological mechanism of the disease remains unknown, we and
others have previously suggested involvement of the comple-
ment system, and in particular the complement factor H gene
(CFH) in cCSC.7,8 Interestingly, CFH variants that confer
increased risk in cCSC have previously been described to be
protective in age-related macular degeneration, and vice
versa.8–10
The complement system consists of three major pathways:
the classical, the lectin, and the alternative pathway.11 CFH is
involved in the alternative pathway and can influence C3b
production by blocking one of the two C3-convertases
(C3bBb). The classical and lectin pathways also play an
important role in C3b production mediated by the other C3-
convertase (C4b2a), of which the complement component 4
(C4) protein is a key factor.12
Copy number variations of the C4 gene have been
associated with several eye diseases and autoimmune disorders
(e.g., Vogt-Koyanagi-Harada and Behc¸et’s disease).13–15 In
addition, Banlaki et al.16 have found that the genomic copy
number of C4B is associated with cortisol release after
adrenocorticotropic hormone (ACTH) stimulation. This is of
particular interest considering that stress, which appears to be
associated with cCSC,4 has a strong influence on the
hypothalamic–pituitary–adrenal (HPA) axis and increases ACTH
release.17
Because of its role in the complement system, and its
association with the HPA axis, we hypothesized that copy
number variation in the C4 gene may be associated with cCSC.
In this study we assessed the copy number variations of the C4
gene in a cCSC cohort.
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MATERIALS AND METHODS
Subjects
In this study, 197 patients diagnosed with cCSC who visited the
outpatient clinic of the Department of Ophthalmology at the
Radboud University Medical Center, Nijmegen, the Nether-
lands, were included (Table 1). The diagnosis cCSC was based
on an extensive ophthalmologic examination including fun-
doscopy, spectral-domain optical coherence tomography,
fluorescein angiography, and indocyanine green angiography.
The definition of typical cCSC used in this study was based on
the previously published subgroups by de Jong et al.,8 and
patients in this study underwent phenotyping by an experi-
enced retina specialist (CJFB) (Fig. 1A–F). Additionally, a total
of 303 control subjects were recruited from the blood bank of
the Radboud University Medical Center (n ¼ 154) and the
European Genetic Database (EUGENDA, www.eugenda.org;
provided in the public domain by the University Hospital of
Cologne, Cologne, Germany and the Radboud University
Medical Center) (n ¼ 149) (Table 1). For this last group,
fundus photographs were graded to rule out any ophthalmo-
logic abnormalities at the moment of inclusion. Informed
consent for the use of DNA for genetic studies was obtained
from all subjects. This study followed the guidelines of the
Declaration of Helsinki and was approved by the local ethics
committee.
Copy Number Determination
DNA was isolated from peripheral blood by using standard
procedures. C4A and C4B copy numbers were determined by
real-time PCR using Taqman genotyping assays (Applied
Biosystems, Thermo Fisher Scientific, Waltham, MA, USA).
The FAM- labe led C4A (Hs07226349_cn) or C4B
(Hs07226350_cn) Taqman copy number assay was combined
with the VIC-labeled Ribonuclease P (RNaseP) reference assay
(catalog No. 4403326), and Taqman genotyping mastermix
(catalog No. 4381656). All samples were tested in duplicate for
C4A and C4B on 384-wells plates by using 10 ng DNA in a total
reaction volume of 10 lL.
Samples with known copy numbers for either C4A (0–4) or
C4B (0–3) were kindly provided by C. Yung Yu.18 These
samples were included as a reference on each plate to facilitate
accurate copy number determination, using the method
described previously.18 In each run the amplification efficien-
cies of the C4A/C4B and RNaseP probes were calculated by
using a serial dilution (50–1.56 ng) of a sample with two C4A
and C4B copies. The primer efficiencies of the probes were
compared and deemed similar if they differed <2%; this was
the case in all runs. Therefore, the efficiencies were not
incorporated into the calculations of the copy numbers.
Polymerase chain reaction was performed with a 7900HT
thermocycler (Applied Biosystems, Thermo Fisher Scientific)
using the following program: 2 minutes at 508C, 10 minutes at
958C, and 40 cycles of 15 seconds at 958C and 60 seconds at
608C. Data were analyzed with the Copycaller software (V2.0;
Applied Biosystems, Thermo Fisher Scientific). Copy numbers
determined by the Copycaller software were corrected by
using the trend line based on the reference samples, as
described before.18 If the results were inconsistent between
the Copycaller output and the values corrected with the trend
line, samples were retested on a new plate in triplicate.
Statistics
The comparison of C4A, C4B, and total C4 copy number
distribution between cCSC patients and controls was per-
formed by means of a Fisher exact test using SPSS Statistics
(V20; IBM Corp., Armonk, NY, USA). Bonferroni correction for
multiple testing was performed for three tests and P values <
0.017 were considered to be statistically significant. A logistic
regression model was constructed to determine the odds ratios
(ORs) for the various copy numbers of C4B. According to
previously published studies, two genomic copy numbers of
C4B are considered to be most common in the healthy
population.15,19 We were able to confirm this in our cohort,
and therefore this copy number was set as reference. In this
model, P values < 0.05 were considered to be significant.
Graphs were generated by using Graphpad Prism (V5; Graph-
pad Software, San Diego, CA, USA).
RESULTS
The copy numbers of C4A and C4B were successfully
determined in 197 cCSC cases and 303 controls. No significant
difference was observed between cases and controls for the
C4A genomic copy number (range: 0–6, P ¼ 0.649; Fig. 2A).
TABLE 1. Demographics of the Study Population
cCSC Patients Controls P Value
No. of subjects 197 303 NA
Sex, male/female 154/43 226/77 0.392
Age, mean 6 SD, y 53 6 10 53 6 11 0.755
Age range, y 29–74 29–77 NA
NA, not annotated; SD, standard deviation.
FIGURE 1. Example of FA of an RE (A) and an LE (C), ICG angiography of an RE (B) and an LE (D), and spectral-domain optical coherence
tomography of an RE (E) and an LE (F) imaging of the phenotypic characteristics of the cCSC cohort used for this study. (A–F) The RE and LE of a
patient demonstrate diffuse hyperfluorescent areas of leakage on FA and ICG angiography (A–D) and subretinal fluid beneath the fovea (E),
illustrative for typical cCSC. FA, fluorescein angiography; ICG, indocyanine green; LE, left eye; RE, right eye.
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The C4B distribution was significantly different between cCSC
patients and controls (range: 0–4, P¼ 0.0018; Fig. 2B). Overall,
cases carried lower copy numbers of C4B than the control
population. The total C4 genomic copy number was not
different in cases compared to controls (P ¼ 0.148; Fig. 2C).
Age and sex were not associated with C4A, C4B, or total C4
genomic copy number (Table 2; data for C4A and total C4 not
shown).
To assess the effect size of the different copy numbers of
C4B on development of cCSC, a logistic regression was
performed (Table 2). The logistic regression model based on
the distribution of C4B between cases and controls was
significant (P ¼ 0.0035; Table 2). Carrying no copies of C4B
conferred increased risk of cCSC (P ¼ 0.039, OR ¼ 2.61, 95%
confidence interval [CI] ¼ 1.05–6.52). A similar trend was
observed for carriers of one copy of C4B, but the results were
not significant (P ¼ 0.080, OR ¼ 1.47, 95% CI ¼ 0.96–2.26).
Carrying three C4B copies was associated with a significantly
decreased risk of cCSC (P¼ 0.014, OR ¼ 0.45, 95% CI ¼ 0.24–
0.85), whereas no significant association with cCSC was
observed in individuals carrying four copies of C4B (P¼ 0.81).
DISCUSSION
Our study results demonstrated that cCSC patients have a
significantly different C4B load as compared to healthy
controls (P ¼ 0.0018). Carrying no copies of C4B was
associated with an increased risk of cCSC (OR ¼ 2.61, 95% CI
¼ 1.05–6.52), whereas carrying three C4B copies was
associated with a decreased risk of cCSC (OR ¼ 0.45, 95% CI
¼ 0.23–0.85). No association with cCSC was observed in
individuals carrying four C4B copies, which is likely due to the
limited sample size of this group (cases, n¼ 4; controls, n¼ 2).
No significant differences were observed between cases and
controls for C4A and total C4 load.
The C4 gene lies within the RP-C4-CYP21-TNX (RCCX)
locus located in the major histocompatability complex (MHC)
region III on chromosome 6 of the human genome.19 The MHC
region contains an elevated level of genomic copy number
variations that are presumably present to increase immunolog-
ic diversity.20 Duplications and deletions in the region have led
to the formation of haplotypes containing variable copies of
the RCCX locus in the human population (Fig. 3B).20–22
Haplotypes containing two or more duplications of the RCCX
locus show extensive variability in their gene content,
generally with complete duplications of the C4 gene (Fig.
3B).21,23 The C4 gene encodes the C4 protein, of which two
variants have been described (C4A/C4B), differing in only four
amino acids encoded by exon 26 (Fig. 3A).24
Copy number variations of either C4A or C4B have been
associated with several systemic diseases with ocular involve-
ment, such as Vogt-Koyanagi-Harada disease, Behc¸et’s disease,
and systemic lupus erythematosus (SLE).13–15 Hou et al.13 have
shown that a lower copy number of C4A and C4B increases the
risk of Vogt-Koyanagi-Harada disease, an autoimmune disorder
characterized by bilateral granulomatous panuveitis. The same
group14 has also demonstrated that higher copy numbers of
C4A confer risk of Behc¸et’s disease, an autoinflammatory
disease, which presents with acute anterior uveitis. Several
studies15,25,26 have shown an association between low copy
numbers of C4 and an increased risk for SLE, an autoimmune
disease that is typically mediated by immune complexes. In the
past, CSC has been described in SLE patients,27,28 but it
remains unclear whether this is a primary manifestation of SLE,
or whether it is a consequence of corticosteroid treatment for
SLE.29,30 Several studies have reported a positive linear
correlation between serum C4 and C4 genomic copy
number,31–33 suggesting that the lower number of C4B copies
in cCSC patients leads to lower systemic C4B levels. This may
indicate that an overall lower activity of the complement
system might be present in cCSC patients.
FIGURE 2. Distribution of the genomic copy numbers of C4A (A), C4B (B), and total C4 (C) in patients with cCSC and controls. Displayed P values
were generated with a Fisher exact test. To correct for multiple testing, P values < 0.017 were considered to be significant.
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Recently, low copy numbers of C4B have been associated
with hyperreactivity of the HPA axis.16 Banlaki et al.16 have
shown that in patients with adrenal incidentaloma and low (<2
copies) C4B genomic copy number, baseline ACTH is
significantly reduced as compared to high (‡2 copies) genomic
copy number of C4B. Moreover, a significantly higher cortisol
response is observed after ACTH stimulation in the patients
with low C4B genomic copy number.16
These results are of interest in the context of cCSC because
of the described clinical associations with stress and the use of
corticosteroids that both exert physiological effects at the level
of the HPA axis.17 Various relatively small studies have studied
cortisol levels in cCSC patients. Although 24-hour urine
samples show elevated cortisol levels in cCSC patients in
certain studies,34,35 these results are not observed in single
serum measurements during set times in other studies.36,37
These discrepancies could be explained by variable cortisol
fluctuations between individuals during the day, and therefore
changes in endogenous cortisol levels cannot be ruled out as a
hallmark of cCSC. It is possible that patients with cCSC
generally have normal cortisol levels but respond differently to
stimulation of the HPA axis. Stress, which also appears to be
associated with cCSC,2,38 stimulates the HPA axis and could
lead to temporarily elevated cortisol levels in patients as
compared to healthy individuals. How high levels of cortisol
can lead to subretinal fluid accumulation is currently
unknown. A study in rats suggests that the disease mechanism
could be mediated by binding of corticosteroids to the
mineralocorticoid receptor.39 In this study, activation of the
mineralocorticoid receptor causes vascular effects similar to
those observed in cCSC,39 but the underlying pathways still
remain to be elucidated.
The mechanism through which low copy numbers of C4B
may lead to hyperresponsiveness of the HPA axis is unclear. It
has been hypothesized that it is not the C4B gene, but rather
the neighboring CYP21A2 gene, that mediates this effect.16
The CYP21A2 gene encodes the enzyme 21-hydroxylase,
which plays an important role in the steroid metabolism
pathway by converting progesterone and 17-a-hydroxyproges-
terone to 11-deoxycorticosterone and 11-deoxycortisol, re-
spectively. Because of the genomic structure of the RCCX
locus, variation in the CYP21A2 gene is in high linkage
disequilibrium with variation in the neighboring C4 gene (C4A
or C4B).16 Therefore, further exploration of the precise
structure and specific variations present in the RCCX locus
may reveal new insights into the pathogenesis of cCSC.
The current study and previous studies identified an
association between complement genes and cCSC,7,8 suggest-
ing that the complement system may be dysregulated in cCSC.
Taken together, these findings may indicate that the immune
system, influenced by environmental factors such as stress,
could play a pivotal role in the pathophysiology of cCSC.
Further studies are necessary to determine the physiological
effects of genetic variation at the C4 gene and the RCCX locus
in cCSC.
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